InvestorsHub Logo

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating
Bullish
Bullish
profile icon
ROCKHard Free
08/03/23 1:31 PM
Bullish
Bullish
profile icon
aquaspin Free
02/15/23 8:51 AM
profile icon
aquaspin Free
12/27/22 10:34 PM
Bullish
Bullish
profile icon
aquaspin Free
12/09/22 8:17 AM
Bullish
Bullish
profile icon
aquaspin Free
10/27/22 8:34 AM
profile icon
aquaspin Free
10/26/22 9:42 PM
profile icon
aquaspin Free
08/15/22 8:05 AM
profile icon
aquaspin Free
08/14/22 10:59 PM
profile icon
aquaspin Free
08/13/22 9:54 AM
profile icon
aquaspin Free
07/29/22 8:42 AM
profile icon
aquaspin Free
05/04/22 8:27 AM
profile icon
aquaspin Free
04/24/22 10:50 PM
profile icon
aquaspin Free
04/24/22 4:47 PM
profile icon
aquaspin Free
12/11/21 10:03 PM
profile icon
aquaspin Free
12/11/21 9:08 AM
profile icon
aquaspin Free
12/11/21 1:11 AM
profile icon
aquaspin Free
11/24/21 10:45 PM
profile icon
aquaspin Free
11/05/21 11:25 PM
profile icon
aquaspin Free
09/30/21 9:36 AM
profile icon
aquaspin Free
09/29/21 1:50 PM
profile icon
aquaspin Free
08/25/21 5:19 PM

Affymax, Inc. (AFFY) RSS Feed

Followers
62
Posters
311
Posts (Today)
0
Posts (Total)
2291
Created
03/24/08
Type
Free
Moderators

http://www.affymax.com/

http://finance.yahoo.com/q/ks?s=AFFY

Affymax, Inc., a biopharmaceutical company, engages in the development of peptide-based drug candidates to enhance the treatment of serious and life-threatening conditions. Its lead product candidate includes Hematide, a synthetic peptide-based erythropoiesis stimulating agent, which is designed to treat anemia associated with chronic kidney disease and cancer. The company is conducting phase II clinical trials of Hematide in dialysis patients, predialysis patients, cancer patients on chemotherapy and patients with PRCA. It is also developing a pipeline of peptide based drug candidates, including Adeptide, a peptide based, non-injectable erythropoiesis stimulating agent; the Innotide program that comprises a family of peptide based drug candidates for use in the area of tissue protection in preclinical models of stroke, myocardial infarct, and renal injury; and Angiotide, a synthetic peptide for treating cancer by blocking angiogenesis, or blood vessel formation in tumors. Affymax has strategic alliances with Takeda Pharmaceutical Company Limited to develop and commercialize Hematide; EntreMed, Inc. for preclinical research of Angiotide; and Nektar Therapeutics AL, Corporation. The company was founded in 2001 and is based in Palo Alto, California.



 

Volume:
Day Range:
Last Trade Time:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
AFFY Latest News
  • No Recent News Available for this company!
New Post